Cythemias
News
Haplo-HSCT appears comparable to fully matched HSCT
Photo by Chad McNeeley A retrospective study suggests that, for patients with hematologic disorders, a haploidentical hematopoietic stem cell...
News
Despite responses, imetelstat won’t move forward in ET
Although trial results suggest imetelstat is effective against essential thrombocythemia (ET), the telomerase inhibitor is only being developed to...
News
Imetelstat in MF: More research needed
The telomerase inhibitor imetelstat has exhibited unique activity in a pilot study of patients with intermediate- or high-risk myelofibrosis (MF...
News
Drugs don’t play well together in MF
Photo courtesy of the CDC Simultaneous administration of lenalidomide and ruxolitinib is not feasible in patients with myelofibrosis (MF),...
News
Team reports phase 3 results with abandoned MPN drug
Researchers have reported results of the phase 3 JAKARTA trial, in which they evaluated the selective JAK2 inhibitor fedratinib in patients with...
News
Inhibitor could treat range of hematologic disorders
A small molecule that targets the sonic Hedgehog signaling pathway has advanced to phase 2 trials in a range of hematologic disorders. In a phase...
News
Methotrexate could treat MPNs cheaply, team says
Photo courtesy of the National Cancer Institute Preclinical research suggests the antineoplastic agent methotrexate (MTX) could be used to treat...
Conference Coverage
HSCT outcomes ‘encouraging’ in JAKi responders
Photo by Chad McNeeley VIENNA—Outcomes of hematopoietic stem cell transplant (HSCT) are encouraging in myelofibrosis (MF) patients who respond...
Conference Coverage
Agent reduces fibrosis, improves platelet counts in MF
VIENNA—The immunotherapeutic agent PRM-151, when given alone or in combination with ruxolitinib, can reduce bone marrow fibrosis and improve...
Conference Coverage
JAK inhibitor can provide long-term disease control in PV
Image courtesy of AFIP VIENNA—Updated results from the phase 3 RESPONSE trial suggest the JAK1/2 inhibitor ruxolitinib can provide long-term...
Conference Coverage
Inhibitor may fulfill unmet need in MF
© ASCO/Zach Boyden-Holmes CHICAGO—The JAK2/FLT3 inhibitor pacritinib may fulfill an unmet need in the treatment of myelofibrosis (MF), according...